Skip to main content

Time to scale up molecular surveillance for anti-malarial drug resistance in sub-saharan Africa

Abstract

Artemisinin resistance has emerged and spread in the Greater Mekong Sub-region (GMS), followed by artemisinin-based combination therapy failure, due to both artemisinin and partner drug resistance. More worrying, artemisinin resistance has been recently reported and confirmed in Rwanda. Therefore, there is an urgent need to strengthen surveillance systems beyond the GMS to track the emergence or spread of artemisinin and partner drug resistance in other endemic settings. Currently, anti-malarial drug efficacy is monitored primarily through therapeutic efficacy studies (TES). Even though essential for anti-malarial drug policy change, these studies are difficult to conduct, expensive, and may not detect the early emergence of resistance. Additionally, results from TES may take years to be available to the stakeholders, jeopardizing their usefulness. Molecular markers are additional and useful tools to monitor anti-malarial drug resistance, as samples collected on dried blood spots are sufficient to monitor known and validated molecular markers of resistance, and could help detecting and monitoring the early emergence of resistance. However, molecular markers are not monitored systematically by national malaria control programmes, and are often assessed in research studies, but not in routine surveillance. The implementation of molecular markers as a routine tool for anti-malarial drug resistance surveillance could greatly improve surveillance of anti-malarial drug efficacy, making it possible to detect resistance before it translates to treatment failures. When possible, ex vivo assays should be included as their data could be useful complementary, especially when no molecular markers are validated.

Background

The development of resistance to the currently used anti-malarial drugs is threatening the major gains in malaria control and elimination made over the last decade. Artemisinin resistance, defined as delayed parasite clearance following treatment with artemisinin monotherapies or artemisinin-based combination therapy (ACT), has been associated with specific mutations in the Plasmodium falciparum kelch 13 gene (Pfk13) [1]. Those validated molecular markers were initially observed in the Greater Mekong Sub-region (GMS), followed by ACT failures due to both artemisinin and partner drug resistance [2,3,4,5,6,7,8,9]. The recent reports of a validated molecular marker of artemisinin resistance in Rwanda [10, 11], and its association with delayed parasite clearance [12], are a major threat to malaria control and elimination in sub-Saharan Africa. Even though the continuous high efficacy of the first- and second-line anti-malarial drugs (artemether-lumefantrine and dihydroartemisinin-piperaquine) in Rwanda is reassuring, an improved scheme for monitoring anti-malarial drug resistance is warranted to mitigate the spread of artemisinin resistance, and ACT failure. Currently, the World Health Organization (WHO) recommends therapeutic efficacy studies (TES) for monitoring drug efficacy and resistance [13], whereas molecular markers and ex vivo monitoring are optional. There is no doubt that anti-malarial drug policy change should be based on TES results; however, molecular and ex vivo data have played an important role in confirming and monitoring artemisinin and partner drug resistance in the GMS [3, 9, 14, 15]. Indeed, partial resistance to artemisinin is difficult to assess in vivo, especially in high transmission settings where acquired immunity is a major confounding factor [16,17,18]. Moreover, TES are time and resources consuming, and may be difficult to conduct in low transmission settings, where the risk of de novo emergence of resistance is highest [19,20,21], due to the low number of patients.

Molecular markers as early warning tools

Molecular markers offer an additional strategy to monitor the early emergence and spread of anti-malarial drug resistance, are not impacted by host immunity, and may be more cost effective when implemented for routine surveillance. Retrospectively, it has been suggested that partial sulfadoxine-pyrimethamine resistance had multiple origins including areas of high transmission in Eastern Africa [22, 23] and, interestingly, the same region seems to be a hotspot for partial artemisinin resistance [12, 24]. Today, tools (molecular markers) to closely monitor the early emergence and spread of artemisinin and partner drug resistance are available. This knowledge should be used to establish a comprehensive molecular surveillance system to avoid the mistakes from the past, when the spread of resistance to anti-malarial monotherapies has been detected at a late stage, contributing to thousands of deaths in the meantime. Molecular markers cannot predict treatment outcome at an individual level, however their increase often precedes that of treatment failures [25]. While monitoring Pfk13 mutations is of paramount importance, monitoring partner drug resistance molecular markers is also crucial [26]. Indeed, high prevalence of Pfk13 validated molecular markers is not usually associated with treatment failure [27], as evidenced by recent data from Rwanda where the efficacy of both first and second-line treatments is still high despite the increasing prevalence of the Pfk13 561 H mutation (Table 1). Currently, molecular surveillance is often done retrospectively based on convenience sampling, and does not provide an accurate estimation of resistance on a national or sub-regional level. For example, when looking at available molecular data for Rwanda, there are large spatiotemporal gaps [10,11,12, 28], and no clear trend is discernible (Table 1). However, high prevalence of the confirmed artemisinin resistance marker 561 H at two sites (Masaka and Rukara) are worrisome, especially as samples have been collected in 2018, and the current situation could be worse. Moreover, the prevalence of this marker has increased from 7 to 20% in Masaka between 2015 and 2018 (Table 1), even though the small sample size does not allow for definitive conclusions, but it is likely that the prevalence is even higher now, and only routine molecular monitoring could accurately assess the trend.

Table 1 Prevalence of PfKelch13 mutations associated with artemisinin resistance in five different sites in Rwanda from 2012 to 2019

Molecular routine surveillance to inform TES

Molecular routine surveillance should not only be conducted in a few sentinel sites, but rather on a large network of health facilities to capture the complex spatial dynamics of evolving resistance [29]. Samples collected from patients attending selected health facilities in the different regions of a country, should be analysed on a regular basis and generated data used to map the spatiotemporal dynamics of molecular markers of interest [29,30,31,32]. The data could be then used to inform and calibrate mathematical models of malaria transmission aiming at guiding interventions strategies, for example to select the sites for TES, using specific thresholds for artemisinin and partner drug resistance markers prevalence, to assess either delayed parasite clearance or treatment failure, respectively [21, 33]. Indeed, it is difficult to predict where resistance will emerge, and a more flexible scheme with rotating sites for TES based on molecular markers prevalence and models prediction may be more appropriate for early detection of resistance. Mathematical models could be used as well to predict when treatment failure could occur based on the molecular markers prevalence, giving more time for policymakers to prepare the change in anti-malarial drug treatment policy [34, 35].

Logistically, sample collection would require only dried blood spots collection at selected health centres when patients have a confirmed malaria diagnosis. The molecular analysis could be centralized at regional, national or sub-regional laboratory to maximize the cost effectiveness of the surveillance system [36]. With the increasing availability of high throughput techniques and assays for molecular markers of resistance genotyping in malaria endemic countries, there is an opportunity to strengthen the capacity of National Malaria Control Programmes (NMCPs) for molecular monitoring of anti-malarial drug resistance [37, 38]. Cross-border collaboration is also critical, especially in regions such as the Great Lakes (Fig. 1), where validated resistance markers have been detected in different countries, including Rwanda, Democratic Republic of the Congo, Kenya, and Tanzania (Fig. 1). Regional monitoring is key to track resistance, as parasites will spread quickly from one country to another. The establishment of regional reference laboratories associated with regional data repositories could facilitate the prompt detection of resistance and early implementation of mitigation strategies; and the malaria community must leverage on the different initiatives on the continent to improve access to the infrastructure and technical expertise for high throughput molecular analyses [39].

Fig. 1
figure1

(adapted from [11, 12, 24])

Map showing countries with WHO validated (in red) and candidate (in blue) artemisinin resistance markers in the Great Lakes region.

Ex vivo assays: a useful, but difficult tool to implement

Ex vivo assays have played an important role in monitoring artemisinin resistance in the GMS [3, 15, 40, 41]. Even though they are often used for phenotypic assays to validate molecular markers of resistance, where available they can be useful to monitor resistance. Indeed, as for molecular markers, immunity is not a confounding factor for ex vivo assays, even though parasite culture may reduce the complexity of the infection by preferentially selecting specific clones. However, ex vivo assays can be a valuable tool for drugs with no validated molecular markers, such as lumefantrine and pyronaridine, the former being the partner drug of the most widely used ACT, and the latter, the most recent ACT partner drug approved by the WHO. Moreover, compared to molecular markers, ex vivo assays are difficult to implement, as fresh blood is required for parasite culture and the high intra and inter-assays variability limits their ability for spatiotemporal dynamics assessment [42].

Conclusions

Anti-malarial drug resistance is a serious threat to malaria control and elimination, and resistance monitoring is crucial to maintain the high efficacy of the current anti-malarial drugs. Anti-malarial drug efficacy monitoring schemes should take the full advantage of molecular and ex vivo culture techniques, as they may be the most appropriate tools to provide early warning signals of anti-malarial drug resistance in high transmission settings. Reinforcing routine molecular surveillance programme could help detecting the emergence and spread of artemisinin and partner drug resistance at an earlier stage, before it translates to treatment failures.

Availability of data and materials

Not applicable.

Abbreviations

ACT:

Artemisinin-based combination therapy

GMS:

Greater Mekong Sub-region

NMCP:

National Malaria Control Programme

TES:

Therapeutic efficacy study

WHO:

World Health Organization

References

  1. 1.

    Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5.

    Article  Google Scholar 

  2. 2.

    Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016;16:357–65.

    CAS  Article  Google Scholar 

  3. 3.

    Duru V, Khim N, Leang R, Kim S, Domergue A, Kloeung N, et al. Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations. BMC Med. 2015;13:305.

    Article  Google Scholar 

  4. 4.

    Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015;59:4719–26.

    CAS  Article  Google Scholar 

  5. 5.

    Lon C, Manning JE, Vanachayangkul P, So M, Sea D, Se Y, et al. Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial. PLoS One. 2014;9:e93138.

    Article  Google Scholar 

  6. 6.

    Saunders DL, Vanachayangkul P, Lon C, US Army Military Malaria Research Program, National Center for Parasitologym Entomology and Malaria Control. Royal Cambodian Armed Forces. Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med. 2014;371:484–5.

    CAS  Article  Google Scholar 

  7. 7.

    Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015;15:683–91.

    CAS  Article  Google Scholar 

  8. 8.

    WHO. Status report on artemisinin resistance and ACT efficacy. Geneva, World Health Organization. 2018. https://www.who.int/malaria/publications/atoz/artemisinin-resistance-august2018/en/.

  9. 9.

    Witkowski B, Khim N, Kim S, Domergue A, Duru V, Menard D. Multiple and successive treatment failures in a patient infected by Plasmodium falciparum in Cambodia and treated by dihydroartemisinin-piperaquine (in French). Bull Soc Pathol Exot. 2016;109:87–90.

    CAS  Article  Google Scholar 

  10. 10.

    Bergmann C, van Loon W, Habarugira F, Tacoli C, Jager JC, Savelsberg D, et al. Increase in kelch 13 polymorphisms in Plasmodium falciparum, Southern Rwanda. Emerg Infect Dis. 2021;27:294–6.

    CAS  Article  Google Scholar 

  11. 11.

    Uwimana A, Legrand E, Stokes BH, Ndikumana JM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602–8.

    CAS  Article  Google Scholar 

  12. 12.

    Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120–8.

    CAS  Article  Google Scholar 

  13. 13.

    WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009. https://apps.who.int/iris/handle/10665/44048.

  14. 14.

    Imwong M, Dhorda M, Myo Tun K, Thu AM, Phyo AP, Proux S, et al. Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. Lancet Infect Dis. 2020;20:1470–80.

    CAS  Article  Google Scholar 

  15. 15.

    Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infect Dis. 2017;17:174–83.

    CAS  Article  Google Scholar 

  16. 16.

    Ataide R, Ashley EA, Powell R, Chan JA, Malloy MJ, O’Flaherty K, et al. Host immunity to Plasmodium falciparum and the assessment of emerging artemisinin resistance in a multinational cohort. Proc Natl Acad Sci USA. 2017;114:3515–20.

    CAS  Article  Google Scholar 

  17. 17.

    Ataide R, Powell R, Moore K, McLean A, Phyo AP, Nair S, et al. Declining transmission and immunity to malaria and emerging artemisinin resistance in Thailand: a longitudinal study. J Infect Dis. 2017;216:723–31.

    CAS  Article  Google Scholar 

  18. 18.

    Lopera-Mesa TM, Doumbia S, Chiang S, Zeituni AE, Konate DS, Doumbouya M, et al. Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity. J Infect Dis. 2013;207:1655–63.

    CAS  Article  Google Scholar 

  19. 19.

    White NJ, Pongtavornpinyo W. The de novo selection of drug-resistant malaria parasites. Proc Biol Sci. 2003;270:545–54.

    CAS  Article  Google Scholar 

  20. 20.

    White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, et al. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J. 2009;8:253.

    Article  Google Scholar 

  21. 21.

    Whitlock AOB, Juliano JJ, Mideo N. Immune selection suppresses the emergence of drug resistance in malaria parasites but facilitates its spread. PLoS Comput Biol. 2021;17:e1008577.

    CAS  Article  Google Scholar 

  22. 22.

    McCollum AM, Poe AC, Hamel M, Huber C, Zhou Z, Shi YP, et al. Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. J Infect Dis. 2006;194:189–97.

    CAS  Article  Google Scholar 

  23. 23.

    Vinayak S, Alam MT, Mixson-Hayden T, McCollum AM, Sem R, Shah NK, et al. Origin and evolution of sulfadoxine resistant Plasmodium falciparum. PLoS Pathog. 2010;6:e1000830.

    Article  Google Scholar 

  24. 24.

    Kayiba NK, Yobi DM, Tshibangu-Kabamba E, Tuan VP, Yamaoka Y, Devleesschauwer B, et al. Spatial and molecular mapping of Pfkelch13 gene polymorphism in Africa in the era of emerging Plasmodium falciparum resistance to artemisinin: a systematic review. Lancet Infect Dis. 2021;21:e82–92.

    CAS  Article  Google Scholar 

  25. 25.

    Nsanzabana C, Hastings IM, Marfurt J, Muller I, Baea K, Rare L, et al. Quantifying the evolution and impact of antimalarial drug resistance: drug use, spread of resistance, and drug failure over a 12-year period in Papua New Guinea. J Infect Dis. 2010;201:435–43.

    CAS  Article  Google Scholar 

  26. 26.

    Nsanzabana C. Resistance to artemisinin combination therapies (ACTs): do not forget the partner drug! Trop Med Infect Dis. 2019;4:26.

    Article  Google Scholar 

  27. 27.

    Tun KM, Jeeyapant A, Myint AH, Kyaw ZT, Dhorda M, Mukaka M, et al. Effectiveness and safety of 3 and 5 day courses of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar. Malar J. 2018;17:258.

    Article  Google Scholar 

  28. 28.

    Tacoli C, Gai PP, Bayingana C, Sifft K, Geus D, Ndoli J, et al. Artemisinin resistance-associated K13 polymorphisms of Plasmodium falciparum in Southern Rwanda, 2010-2015. Am J Trop Med Hyg. 2016;95:1090–3.

    Article  Google Scholar 

  29. 29.

    Aydemir O, Janko M, Hathaway NJ, Verity R, Mwandagalirwa MK, Tshefu AK, et al. Drug-resistance and population structure of Plasmodium falciparum across the Democratic Republic of Congo using high-throughput molecular inversion probes. J Infect Dis. 2018;218:946–55.

    CAS  Article  Google Scholar 

  30. 30.

    Ehrlich HY, Bei AK, Weinberger DM, Warren JL, Parikh S. Mapping partner drug resistance to guide antimalarial combination therapy policies in sub-Saharan Africa. Proc Natl Acad Sci USA. 2021;118:e2100685118.

    CAS  Article  Google Scholar 

  31. 31.

    Ehrlich HY, Jones J, Parikh S. Molecular surveillance of antimalarial partner drug resistance in sub-Saharan Africa: a spatial-temporal evidence mapping study. Lancet Microbe. 2020;1:e209–17.

    CAS  Article  Google Scholar 

  32. 32.

    Otienoburu SD, Suay I, Garcia S, Thomas NV, Srisutham S, Bjorkman A, et al. An online mapping database of molecular markers of drug resistance in Plasmodium falciparum: the ACT Partner Drug Molecular Surveyor. Malar J. 2019;18:12.

    Article  Google Scholar 

  33. 33.

    Hastings IM, Hardy D, Kay K, Sharma R. Incorporating genetic selection into individual-based models of malaria and other infectious diseases. Evol Appl. 2020;13:2723–39.

    Article  Google Scholar 

  34. 34.

    malERA Refresh Consultative Panel on Combination Interventions and Modelling. malERA: an updated research agenda for combination interventions and modelling in malaria elimination and eradication. PLoS Med. 2017;14:e1002453.

    Article  Google Scholar 

  35. 35.

    Slater HC, Griffin JT, Ghani AC, Okell LC. Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa. Malar J. 2016;15:10.

    Article  Google Scholar 

  36. 36.

    Nsanzabana C. Strengthening surveillance systems for malaria elimination by integrating molecular and genomic data. Trop Med Infect Dis. 2019;4:139.

    Article  Google Scholar 

  37. 37.

    Dalmat R, Naughton B, Kwan-Gett TS, Slyker J, Stuckey EM. Use cases for genetic epidemiology in malaria elimination. Malar J. 2019;18:163.

    Article  Google Scholar 

  38. 38.

    Ndiaye YD, Hartl DL, McGregor D, Badiane A, Fall FB, Daniels RF, et al. Genetic surveillance for monitoring the impact of drug use on Plasmodium falciparum populations. Int J Parasitol Drugs Drug Resist. 2021;17:12–22.

    Article  Google Scholar 

  39. 39.

    Inzaule SC, Tessema SK, Kebede Y, Ogwell Ouma AE, Nkengasong JN. Genomic-informed pathogen surveillance in Africa: opportunities and challenges. Lancet Infect Dis. 2021;21:e281–9.

    CAS  Article  Google Scholar 

  40. 40.

    Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis. 2013;13:1043–9.

    CAS  Article  Google Scholar 

  41. 41.

    Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeung N, et al. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother. 2013;57:914–23.

    CAS  Article  Google Scholar 

  42. 42.

    Nsanzabana C, Djalle D, Guerin PJ, Menard D, Gonzalez IJ. Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape. Malar J. 2018;17:75.

    Article  Google Scholar 

Download references

Acknowledgements

I would like to thank my colleagues for fruitful discussions.

Funding

None.

Author information

Affiliations

Authors

Contributions

CN designed and wrote this opinion article. The author read and approved the final manuscript.

Author’s informations

CN was trained in molecular epidemiology at the Université de Neuchâtel and Swiss Tropical and Public health institute in Switzerland. He has more than 17 years’ experience in malaria research going from basic to translational and implementation research, mainly on anti-malarial drug efficacy, anti-malarial drug resistance and mode of action, including postdoctoral experience at the University of California San Francisco, and University of Oxford with the WorldWide Antimalarial Resistance Network (WWARN). He is currently leading the malaria genotyping group in the Diagnostics Unit at the Swiss Tropical and Public Health Institute.

Corresponding author

Correspondence to Christian Nsanzabana.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The author declares no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nsanzabana, C. Time to scale up molecular surveillance for anti-malarial drug resistance in sub-saharan Africa. Malar J 20, 401 (2021). https://0-doi-org.brum.beds.ac.uk/10.1186/s12936-021-03942-5

Download citation